Abeona Therapeutics
ABEO
33 hedge funds and large institutions have $21.2M invested in Abeona Therapeutics in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 5 reducing their positions, and 12 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 5
4.98% less ownership
Funds ownership: 47.47% → 42.5% (-5%)
18% less funds holding
Funds holding: 40 → 33 (-7)
37% less capital inflows, than outflows
Capital inflows: $4.77M | Capital outflows: $7.53M
58% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nantahala Capital Management
New Canaan,
Connecticut
|
+$3.02M |
| 2 |
Western Standard LLC
Los Angeles,
California
|
+$586K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$433K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$373K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$88.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
-$3.41M |
| 2 |
EcoR1 Capital
San Francisco,
California
|
-$3.35M |
| 3 |
ACM
Altium Capital Management
New York
|
-$335K |
| 4 |
XTX Topco
George Town,
Cayman Islands
|
-$160K |
| 5 |
Jane Street
New York
|
-$115K |
ABEO Hedge Fund Activity: Q1 2023 in Review
33 of the 6,289 institutional investors tracked by Wall St. Rank reported a position in Abeona Therapeutics (ABEO) for Q1 2023, worth a combined $21.2M — down 25% from $28.5M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of ABEO and 5 opened new positions — a net loss of 7 holders — while 5 trimmed existing stakes and 10 added.
The largest buyer was Nantahala Capital Management, adding an estimated $3.02M. The largest seller was Armistice Capital, exiting entirely with an estimated $3.41M sold.
- 33 institutional investors held Abeona Therapeutics (ABEO) as of Q1 2023, down from 40 in Q4 2022.
- Funds reported $21.2M of Abeona Therapeutics stock for Q1 2023, down 25% quarter-over-quarter.
- 5 funds opened new Abeona Therapeutics positions in Q1 2023 and 12 closed out, a net change of -7 holders.
- The largest Abeona Therapeutics buyer in Q1 2023 was Nantahala Capital Management, an estimated $3.02M added.
- The largest Abeona Therapeutics seller in Q1 2023 was Armistice Capital, an estimated $3.41M sold.
Based on aggregated 13F filings for Q1 2023.